Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.

Abstract: The present invention relates to a tourniquet (1) comprising: • a support (2) for surrounding a first portion of a limb, • an elastic sleeve (4) to be held in a stretched position around the support (2), the support (2) preventing contraction of the elastic sleeve (4), • a grip element (8) which is movable relative to the support (2), • a drive element (6) for driving the elastic sleeve (4), when the grip element (8) is moved manually relative to the support (2), from its stretched position around the support to a blood vessel constricting position wherein the elastic sleeve (4) surrounds a second portion of the limb, adjacent to the first portion of the limb but not surrounded by the support (2), in such a way that the elastic sleeve (4) can contract by resilient return, and thus compress the second portion of the limb.

Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.

Abstract: A method for diagnosing or prognosing, multiple sclerosis including the steps of (a) measuring the amount of at least one first protein as set forth in SEQ ID NO: 1, the at least first protein belonging to the group of proteins: a first protein, a second protein, a third protein, a fourth protein and a fifth protein, as set forth in SEQ ID NO 1 to 5, (b) comparing the amount of the at least first protein with the amount of the same protein in a control sample, and (c) determining the status of the biological sample.

Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

Abstract: The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.

Abstract: A device for acclimatising at altitude comprising a breathing mask defining a confined air space when it is placed on the face of a user. The mask comprising a suction valve to let the surrounding air enter inside the confined space when breathing in; an expiration valve to let air exit with a determined resistance, so as to create an overpressurisation of air in the confined space, when breathing out; and a sensor to establish information about the pressure of the confined space behind. The acclimatisation device in addition comprises a unit for processing the pressure information configured to establish a breathing characteristic of the user and compare it to at least one target value, in view of recommending to them an adjustment of the breathing mode thereof. A method for functioning this device is also provided.

Abstract: The present invention relates to a compound having the following formula (I): (I) wherein: —R is a (C1-C6)alkyl group; —R? is preferably H; —Ar is a (C5-C12)arylene radical; —X1 is —C(?O)—or —SO2—; and —R? is chosen from the group consisting of possibly substituted (C1-C6)alkyl, heteroaryl, (C5-C12)aryl, and (hetero)cycloalkyl groups, or a pharmaceutically acceptable salt and/or tautomeric form thereof, or its racemates, diastereomers or enantiomers.

Abstract: Methods and systems are provided for decoding movement intentions using functional ultrasound (fUS) imaging of the brain. In one example, decoding movement intentions include determining a memory phase of a cognitive state of the brain, the memory phase between a gaze fixation phase and movement execution phase, and determining one or more movement intentions including one or more of intended effector (e.g., hand, eye) and intended direction (e.g., right, left) according to a machine learning algorithm trained to classify one or more movement intentions simultaneously.

Abstract: A medical device includes a catheter, which includes a first lumen for injection of a first volume of a treatment solution, the first lumen opening out at the distal end of the catheter; and a junction element extending the first lumen at the end of the catheter including a diameter at the distal end thereof less than the diameter of the catheter.

Abstract: The present invention relates to the treatment of HCMV relates diseases. The inventors conducted a study to find an essential domain of pUL56 for its interaction with pUL89 which is important in the effect of the CMV. Sequences alignments allowed them to predict one sequence in C-terminal of pUL56 potentially necessary for interaction with pUL89. BAC mutagenesis and AlphaLISA technologies using purified proteins allowed to validate that the short sequence 671WMVVKYMGFF680 (SEQ ID NO: 1) in C-terminal of pUL56 is involved in interaction with pUL89. Knowing this important information, antibodies directed against this sequence or peptides derived from this sequence could be useful to invalidate the interaction of pUL56 to pUL89 and thus to treat HCMV related diseases.

Abstract: This method for acquiring a spatial map of auditory perception of a subject comprises a plurality of successive test sequences, each test sequence comprising steps of: a) calibration (1002) of the subject's position, by displaying instructions to the subject, using a head-mounted visual display system worn by the subject, in order to acquire a reference position of the subject, the subject's position being measured using a video motion capture system by measuring the spatial coordinates of a first optical marker worn by the subject, b) choosing (1004) spatial coordinates of a target location of a sound source, said target cation being located around the subject, c) emitting (1006) a predefined sound, using a sound source placed at said target location, d) in response to acquisition instructions generated by the subject using an acquisition interface, acquiring (1008) an estimated location of said sound source, by using the video motion capture system to measure the spatial coordinates of a second optical mark

Abstract: A vibrotactile stimulation device intended to be applied against a body environment (MC) to be stimulated and having a vibrating effector suitable for applying, to the environment, pulses of mechanical vibrational energy, and a controller controlling the effector according to stimulation rules. The device further includes vibration detector suitable for being exposed to the body environment in order to receive a part of the vibrational energy transmitted to the environment during the application of the pulses of vibrational energy, and determine a transmission characteristic of the vibrational energy between the effector and the environment to be stimulated, the vibration detector being linked to the controller. An application to improving the efficacy of body stimulation in combating sleep apnea is also disclosed.

Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Abstract: A regenerative material in the connective tissues (such as bone, dentin or pulp) regeneration field. More precisely, a connective tissue regenerative material, preferably a bone, dentin or pulp regenerative material, including: a porous polymer matrix having interconnected pores; and non-hydrated calcium silicate particles; wherein: the polymer matrix is anhydrous; the non-hydrated calcium silicate particles have a d50granulometry, preferably ranging from 0.05 ?m to less than the average diameter size of the pores of the matrix; and the non-hydrated calcium silicate particles being coated on the inside walls of the pores of the matrix. Also, a method for preparing the connective tissue regenerative material and uses of the regenerative materials, such as in the dental field; especially, for providing regenerative materials with improved biomechanical and osteoinductive properties (i.e.

Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.

Abstract: The present invention generally relates to an immunogenic construct, useful for redirecting an EBV-existing immune response towards an undesired target cell and/or microorganism, to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.

Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.

Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non invasive methods and kits for determining the quality of an embryo by determining the level of the cell free nucleic acids and/or determining the presence and/or expression level of at least one specific nucleic acid sequence in the nucleic acid extraction.

Abstract: A method for the generation of a consciousness indicator for a non-communicating subject, including generating a sensory stimulation involving at least one of the five senses, the sensory stimulation having multiple consecutive stimuli including at least a first stimulus and a second stimulus relating to the same sense and different from one another, measuring an electrocardiographic signal of the subject during the generation of the sensory stimulation, extracting at least one EKG feature from the electrocardiographic signal associated to cognitive processes and generating a consciousness indicator using the EKG features as input of a classifier.